 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Working to Stay Afloat, Marina Aims to Avoid Becoming Latest RNAi Drug Disappearing Act
October 18, 2012
Working to Stay Afloat, Marina Aims to Avoid Becoming Latest RNAi Drug Disappearing Act
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Maturing RNAi Industry Suggests It Spends Time in Court and in the Lab
August 25, 2011 / Gene Silencing News - IRS Awards $7M to RNAi, microRNA Firms; Grants Shed Light on Company Pipelines
November 4, 2010 / Gene Silencing News - As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years'
December 8, 2011 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - RXi Q1 Loss Rises on Opko Deal Charge
May 16, 2013 / Gene Silencing News